Related references
Note: Only part of the references are listed.A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies
Philippe Armand et al.
LEUKEMIA (2021)
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sezary Syndrome: A Multicenter Phase II Study
Michael S. Khodadoust et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Myeloid immunosuppression and immune checkpoints in the tumor microenvironment
Kyohei Nakamura et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression
Xiang-Nan Jiang et al.
ONCOIMMUNOLOGY (2020)
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Justin Kline et al.
BLOOD (2020)
Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment
Yangjing Zhao et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Li-Tzong Chen et al.
GASTRIC CANCER (2020)
PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation
Kenji Shimizu et al.
MOLECULAR CELL (2020)
Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
Tomohiro Aoki et al.
CANCER DISCOVERY (2020)
Targeting an adenosine-mediated don't eat me signal augments anti-lymphoma immunity by anti-CD20 monoclonal antibody
Kyohei Nakamura et al.
LEUKEMIA (2020)
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai et al.
NATURE IMMUNOLOGY (2020)
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cancer immunoediting and immune dysregulation in multiple myeloma
Kyohei Nakamura et al.
BLOOD (2020)
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma
Colm Keane et al.
BLOOD ADVANCES (2020)
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden
Winnie S. Liang et al.
ONCOLOGIST (2019)
PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype
James Godfrey et al.
BLOOD (2019)
Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas
Keisuke Kataoka et al.
LEUKEMIA (2019)
Genomic correlates of response to immune checkpoint blockade
Tanya E. Keenan et al.
NATURE MEDICINE (2019)
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition
Daisuke Ennishi et al.
CANCER DISCOVERY (2019)
Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL
Ziju Y. Xu-Monette et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study
Maria-Victoria Mateos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
Stefan K. Barta et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells
Takahiro Kamiya et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Radhakrishnan Ramchandren et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses
Daisuke Sugiura et al.
SCIENCE (2019)
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
Yan Zhang et al.
CELL RESEARCH (2019)
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
Guillaume Manson et al.
EUROPEAN JOURNAL OF CANCER (2019)
SAFETY OF LISOCABTAGENE MARALEUCEL GIVEN WITH DURVALUMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA: FIRST RESULTS FROM THE PLATFORM STUDY
T. Siddiqi et al.
HEMATOLOGICAL ONCOLOGY (2019)
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
Hao Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Amira A. Barkal et al.
NATURE (2019)
Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasmas
Cansu Cimen Bozkus et al.
CANCER DISCOVERY (2019)
A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia
Dan Liao et al.
FRONTIERS IN PHARMACOLOGY (2019)
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
Maria-Victoria Mateos et al.
LANCET HAEMATOLOGY (2019)
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Zafar Usmani et al.
LANCET HAEMATOLOGY (2019)
CTLA-4-mediated transendocytosis of costimulatory molecules primarily targets migratory dendritic cells
Vitalijs Ovcinnikovs et al.
SCIENCE IMMUNOLOGY (2019)
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer
Marian L. Burr et al.
CANCER CELL (2019)
Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
Ken Kato et al.
LANCET ONCOLOGY (2019)
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade
Daniel A. Rauch et al.
BLOOD (2019)
Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1st FLOR' Study
Allison Barraclough et al.
BLOOD (2019)
A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Swami P. Iyer et al.
BLOOD (2019)
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang et al.
CELL (2019)
Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
Daisuke Ennishi et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
Stephen M. Ansell et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways
Yunlong Zhao et al.
IMMUNITY (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study
Anas Younes et al.
LANCET HAEMATOLOGY (2019)
A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
James J. Harding et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma
Ashraf Z. Badros et al.
BLOOD ADVANCES (2019)
Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy
Jithendra Kini Bailur et al.
JCI INSIGHT (2019)
Phagocytosis checkpoints as new targets for cancer immunotherapy
Mingye Feng et al.
NATURE REVIEWS CANCER (2019)
The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy
M. O. Holmstrom et al.
LEUKEMIA (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma
Camille Guillerey et al.
BLOOD (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader et al.
BLOOD (2018)
Are EBV-related and EBV-unrelated Hodgkin lymphomas different with regard to susceptibility to checkpoint blockade?
Antonino Carbone et al.
BLOOD (2018)
Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment
Kyohei Nakamura et al.
CANCER CELL (2018)
TIM-3 Regulates CD103(+) Dendritic Cell Function and Response to Chemotherapy in Breast Cancer
Alvaro de Mingo Pulido et al.
CANCER CELL (2018)
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure
Amer M. Zeidan et al.
CLINICAL CANCER RESEARCH (2018)
CD8+ T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients
Mengjie Wang et al.
CLINICAL IMMUNOLOGY (2018)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression
Heng Lin et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
Xin Li et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Joseph A. Fraietta et al.
NATURE MEDICINE (2018)
Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy
Lee Ratner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Mauro P. Avanzi et al.
CELL REPORTS (2018)
Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
Yunlong Zhao et al.
CELL REPORTS (2018)
PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface
Apoorvi Chaudhri et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma
Xiaoxiao Wang et al.
NEOPLASIA (2018)
Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade
Simone A. Minnie et al.
BLOOD (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Sarwish Rafiq et al.
NATURE BIOTECHNOLOGY (2018)
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Spencer C. Wei et al.
CANCER DISCOVERY (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
Niken M. Mahaweni et al.
FRONTIERS IN IMMUNOLOGY (2018)
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining
Sarah Pericart et al.
CANCERS (2018)
Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia
Amanda M. Li et al.
BLOOD (2018)
Clinical assessment of immune-related adverse events
Aaron Sosa et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy
Amira A. Barkal et al.
NATURE IMMUNOLOGY (2018)
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
Zijun Y. Xu-Monette et al.
BLOOD (2018)
Redirecting T cells to hematological malignancies with bispecific antibodies
Mireya Paulina Velasquez et al.
BLOOD (2018)
Emerging treatments for classical myeloproliferative neoplasms
Alessandro M. Vannucchi et al.
BLOOD (2017)
The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
M. O. Holmstrom et al.
LEUKEMIA (2017)
LAG3 (CD223) as a cancer immunotherapy target
Lawrence P. Andrews et al.
IMMUNOLOGICAL REVIEWS (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
James N. Kochenderfer et al.
MOLECULAR THERAPY (2017)
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis
Tim Wartewig et al.
NATURE (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent
Alice O. Kamphorst et al.
SCIENCE (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
Levi J. Rupp et al.
SCIENTIFIC REPORTS (2017)
Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment
Oladapo O. Yeku et al.
SCIENTIFIC REPORTS (2017)
Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy
Anne-Sophie Gautron et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study.
Loretta J. Nastoupil et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing L-asparaginase
Yok-Lam Kwong et al.
BLOOD (2017)
T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy
David J. Chung et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
T-Cell Immunoglobulin and ITIM Domain (TIGIT) Associates with CD8+ T-Cell Exhaustion and Poor Clinical Outcome in AML Patients
Yaxian Kong et al.
CLINICAL CANCER RESEARCH (2016)
Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy
Stephen J. Blake et al.
CLINICAL CANCER RESEARCH (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Margaretha G. M. Roemer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identification of CD112R as a novel checkpoint for human T cells
Yuwen Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2016)
Targeting natural killer cells in cancer immunotherapy
Camille Guillerey et al.
NATURE IMMUNOLOGY (2016)
Driving CAR T-cells forward
Hollie J. Jackson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Production of Anti-CD19 CAR T Cells for ZUMA-3 and-4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)
Marianna Sabatino et al.
BLOOD (2016)
Pembrolizumab, a PD-1 Inhibitor, in Patients with Myelodysplastic Syndrome (MDS) after Failure of Hypomethylating Agent Treatment
Guillermo Garcia-Manero et al.
BLOOD (2016)
A TIM-3/Gal-9 Autocrine Stimulatory Loop Drives Self-Renewal of Human Myeloid Leukemia Stem Cells and Leukemic Progression
Yoshikane Kikushige et al.
CELL STEM CELL (2015)
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma
Don M. Benson et al.
CLINICAL CANCER RESEARCH (2015)
Regulatory T-cell deficiency and immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like disorder caused by loss-of-function mutations in LRBA
Louis-Marie Charbonnier et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
TIGIT predominantly regulates the immune response via regulatory T cells
Sema Kurtulus et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression
Kevin J. Curran et al.
MOLECULAR THERAPY (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy
Bernice Lo et al.
SCIENCE (2015)
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
David L. Porter et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Epstein-Barr Virus-Associated Lymphomas
Ewelina Grywalska et al.
SEMINARS IN ONCOLOGY (2015)
PD-1hiTIM-3+ T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation
Y. Kong et al.
BLOOD CANCER JOURNAL (2015)
Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study
Colm Keane et al.
LANCET HAEMATOLOGY (2015)
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia
H. J. Pegram et al.
LEUKEMIA (2015)
A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma
Neha Korde et al.
HAEMATOLOGICA (2014)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
Ana C. Anderson
CANCER IMMUNOLOGY RESEARCH (2014)
The tumour microenvironment in B cell lymphomas
David W. Scott et al.
NATURE REVIEWS CANCER (2014)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
James N. Kochenderfer et al.
BLOOD (2012)
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission
Norbert Vey et al.
BLOOD (2012)
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
Don M. Benson et al.
BLOOD (2012)
Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
Seng-Ryong Woo et al.
CANCER RESEARCH (2012)
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Michael R. Green et al.
CLINICAL CANCER RESEARCH (2012)
CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma
Naveen Dakappagari et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2012)
Constitutive Clathrin-mediated Endocytosis of CTLA-4 Persists during T Cell Activation
Omar S. Qureshi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
Tadashi Yokosuka et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
Emily Corse et al.
JOURNAL OF IMMUNOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Anti-TIM3 Antibody Promotes T Cell IFN-γ-Mediated Antitumor Immunity and Suppresses Established Tumors
Shin Foong Ngiow et al.
CANCER RESEARCH (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma
Mark P. Chao et al.
CELL (2010)
TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Yoshikane Kikushige et al.
CELL STEM CELL (2010)
Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
Xiaoyuan Huang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Kaori Sakuishi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
Nitya Jain et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
Randall H. Friedline et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
Raanan Berger et al.
CLINICAL CANCER RESEARCH (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
LAG-3 regulates CD8+T cell accumulation and effector function in murine self- and tumor-tolerance systems
Joseph F. Grosso et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Blockade of CTLA-4 on CD4+ CD25+ regulatory T cells abrogates their function in vivo
Simon Read et al.
JOURNAL OF IMMUNOLOGY (2006)
Self-tolerance of natural killer cells
David H. Raulet et al.
NATURE REVIEWS IMMUNOLOGY (2006)
The SIRP family of receptors and immune regulation
AN Barclay et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells
A Boasso et al.
BLOOD (2005)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse
T Pentcheva-Hoang et al.
IMMUNITY (2004)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
JG Egen et al.
IMMUNITY (2002)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
